Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 4/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9563923 | 0.80 | ALDH1A1 (0.43) | ALDH1A1HPGDCYP1A2MAPTRAB9A | |
| SCHEMBL9564013 | 0.77 | LMNA (0.50) | ALDH1A1HPGDCYP1A2MAPTRAB9A | |
| SCHEMBL9564059 | 0.76 | HPGD (0.45) | ALDH1A1HPGDCYP1A2MAPTRAB9A | |
| SCHEMBL13873464 | 0.76 | LMNA (0.50) | SMN1; SMN2LMNA | |
| SCHEMBL12139570 | 0.74 | ALDH1A1 (0.38) | ALDH1A1HPGDCYP1A2MAPTRAB9A | |
| SCHEMBL1360134 | 0.72 | HPGD (0.47) | ALDH1A1HPGDCYP1A2MAPTRAB9A | |
| SCHEMBL709354 | 0.70 | LMNA (0.39) | ALDH1A1HPGDMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL709348 | 0.70 | HPGD (0.45) | ALDH1A1HPGDCYP1A2MAPTRAB9A | |
| SCHEMBL6013194 | 0.69 | HPGD (0.44) | ALDH1A1HPGDCYP1A2MAPTRAB9A | |
| SCHEMBL13267665 | 0.69 | LMNA (0.39) | ALDH1A1HPGDMAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090098059-A1 | CONTRAST AGENTS | WYNN DUNCAN | 2009-04-16 | — | — | US | disclosed |
| EP-2021317-A1 | CONTRAST AGENTS | GE Healthcare AS (NO) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007133090-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090098059-A1 | CONTRAST AGENTS | IPO4, IPO11, IPO8 | ALDH1A1 4130/4885HPGD 2630/4885KMT2A 4163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.